KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dynavax Technologies (DVAX) Research & Development: 2009-2024

Historic Research & Development for Dynavax Technologies (DVAX) over the last 16 years, with Dec 2024 value amounting to $61.5 million.

  • Dynavax Technologies' Research & Development rose 32.72% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.8 million, marking a year-over-year increase of 29.44%. This contributed to the annual value of $61.5 million for FY2024, which is 12.14% up from last year.
  • As of FY2024, Dynavax Technologies' Research & Development stood at $61.5 million, which was up 12.14% from $54.9 million recorded in FY2023.
  • Over the past 5 years, Dynavax Technologies' Research & Development peaked at $61.5 million during FY2024, and registered a low of $28.6 million during FY2020.
  • For the 3-year period, Dynavax Technologies' Research & Development averaged around $54.3 million, with its median value being $54.9 million (2023).
  • In the last 5 years, Dynavax Technologies' Research & Development slumped by 54.10% in 2020 and then surged by 44.59% in 2022.
  • Dynavax Technologies' Research & Development (Yearly) stood at $28.6 million in 2020, then grew by 12.66% to $32.2 million in 2021, then spiked by 44.59% to $46.6 million in 2022, then climbed by 17.78% to $54.9 million in 2023, then increased by 12.14% to $61.5 million in 2024.